MBX Biosciences (MBX) Research & Development (2023 - 2026)
MBX Biosciences (MBX) posted Research & Development of $1.3 million for Q1 2026, down 93.56% sequentially from $19.8 million in Q4 2025, and down 94.32% YoY from $22.4 million in Q1 2025.
MBX Biosciences (MBX) Research & Development (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Research & Development for 4 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Research & Development fell 94.32% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.0 million (up 44.77% YoY) and the FY2025 annual result came in at $79.2 million, up 5802.98% from the prior year.
- Research & Development retreated to $1.3 million in Q1 2026 per MBX's latest filing, from $19.8 million in the prior quarter.
- Over five years, Research & Development peaked at $22.4 million in Q1 2025 and troughed at -$18.6 million in Q4 2023.
- A 4-year average of $9.1 million and a median of $11.0 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2025 and 2026: Research & Development surged 4850.84% in 2025, then tumbled 94.32% in 2026.
- Over 4 years, Research & Development stood at -$18.6 million in 2023, then soared by 103.08% to $572000.0 in 2024, then soared by 3354.37% to $19.8 million in 2025, then tumbled by 93.56% to $1.3 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.3 million, $19.8 million, and $19.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | 30.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.99 Mn |
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 19.76 Mn |
| Sep 30, 2025 | 19.27 Mn |
| Jun 30, 2025 | 17.72 Mn |
| Mar 31, 2025 | 22.41 Mn |
| Dec 31, 2024 | 572,000.00 |
| Sep 30, 2024 | 16.75 Mn |
| Jun 30, 2024 | 358,000.00 |
| Mar 31, 2024 | 11.05 Mn |
| Dec 31, 2023 | -18.59 Mn |
| Sep 30, 2023 | 9.07 Mn |